Position of the Transparency Council – Litfulo (ritlecitinib)
At its meeting on 27 January 2025, the Transparency Council adopted position No. 14/2025 on the evaluation of the drug Litfulo (ritlecitinib) under the drug program: “Treatment of patients with severe alopecia areata (ICD-10: L63).”
Publication of the position >>